Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

00 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRME
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
(Date:8/21/2014)... SoundConnect , a unified communication ... of the nation’s Fastest Growing Private Companies by ... consecutive year. Inc. magazine today ranked SoundConnect NO. ... exclusive ranking of the nation's fastest-growing private companies. ... the most important segment of the economy—America’s independent ...
(Date:8/21/2014)... 21, 2014 On Wednesday of last week ... use Redox Signaling molecules, became available for purchase in Australia ... "The way that RENU 28 works is, if you think ... of the rate of cellular renewal within your body. If ... of that rate of cellular renewal. What RENU 28 does ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3RENU 28 Skin Care Now Available in Australia and New Zealand 2
... 2 Study Planned, WESTMINSTER, Colo., Oct. 25 ... biopharmaceutical company focused on,the development and commercialization of ... announced that results from three PDX,studies were presented ... 22-26, 2007 in San Francisco, California. The posters,described ...
... (NASDAQ: XTLB )(LSE: XTL)(TASE: XTL) today announced ... investors relating to,a private placement of an aggregate ... represented by American Depositary Receipts (ADRs). The,lead investors ... Quogue,Capital LLC, SCO Capital Partners and Versant Capital. ...
... Oct. 25 Maxygen, Inc.,(Nasdaq: MAXY ), a ... today announced that it will present at two,upcoming investor ... Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference ... World Markets 18th Annual Healthcare Conference Tuesday, November ...
Cached Biology Technology:Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 2Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 4XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 2XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 3
(Date:8/20/2014)... 20, 2014 George E. Fox, a John and Rebecca ... Houston (UH), was named a fellow in the International Society ... , Fox is one of four members two from ... chosen as fellows in 2014. Fellows are elected every three ... than 500 members from more than 20 countries, the ISSOL ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... Love songs aren,t only for soft rock FM stations ... University and the University of Texas at Austin are believed to ... the winged creatures. Their work is published in the current issue ... Bohn and Mike Smotherman in the Department of Biology at Texas ...
... the boreal forest across large stretches of Russia, Canada ... a team of international researchers has found. The ... of Adelaide in Australia and the National University of ... boreal forests in order to secure biodiversity and prevent ...
... 24 A long-term field and DNA study by ... University, University of Miami, Field Museum of Chicago and ... the Bimini islands, Bahamas, tend to stay near their ... conservation typically focuses on baby sharks confined to shallow ...
Cached Biology News:Bats use love songs during mating, researchers say 2World's last great forest under threat: New study 2Scientists shed new light on behavior of shark 'tweens' and 'teenagers' 2Scientists shed new light on behavior of shark 'tweens' and 'teenagers' 3
Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
... Ultrapure C 25 H 27 N 2 ... PRODUCT SPECIFICATIONS Form: Dark burgundy metallic powder Identity: ... 2 O, 1 cm): greater than or equal ... Drying: less than or equal to 10.0% lambda ...
... is the research-grade spectrofluorometer with a minimum ... S/N ratio 200 or greater for the ... especially designed to keep in mind in ... kinetics, stopped-flow, titration, or anisotropic measurements. ,The ...
... Microarrays designed for genome-wide microRNA expression ... powerful Paraflo microfluidic on-chip synthesis platform. These ... comprehensive microRNA Expression Profiling Service. ... contains all known cow microRNAs (108 unique ...
Biology Products: